Cibus, Inc. (NASDAQ:CBUS) Shares Sold by FineMark National Bank & Trust

FineMark National Bank & Trust cut its position in Cibus, Inc. (NASDAQ:CBUS) by 50.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,500 shares of the company’s stock after selling 20,488 shares during the period. FineMark National Bank & Trust’s holdings in Cibus were worth $57,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. IFP Advisors Inc purchased a new position in Cibus in the 4th quarter valued at $36,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Cibus in the third quarter valued at about $44,000. Virtu Financial LLC purchased a new position in shares of Cibus in the third quarter worth about $48,000. Sei Investments Co. acquired a new position in Cibus during the fourth quarter worth about $49,000. Finally, HighTower Advisors LLC grew its stake in Cibus by 20.6% during the 3rd quarter. HighTower Advisors LLC now owns 16,125 shares of the company’s stock valued at $52,000 after acquiring an additional 2,750 shares in the last quarter. 33.81% of the stock is currently owned by hedge funds and other institutional investors.

Cibus Trading Down 5.3 %

Cibus stock opened at $1.98 on Thursday. The stock has a market cap of $52.38 million, a P/E ratio of -0.09 and a beta of 2.04. The company has a 50-day moving average price of $2.31 and a 200 day moving average price of $3.27. Cibus, Inc. has a 12-month low of $1.80 and a 12-month high of $22.99.

Cibus (NASDAQ:CBUS) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.19). The firm had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $1.13 million. Cibus had a negative net margin of 10,724.78% and a negative return on equity of 28.17%. As a group, analysts forecast that Cibus, Inc. will post -2.96 EPS for the current year.

Analyst Upgrades and Downgrades

CBUS has been the topic of a number of research reports. Canaccord Genuity Group decreased their target price on shares of Cibus from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Cibus in a research note on Friday, March 21st.

Cibus Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.